LENSAR, Inc. (LNSR) stock
Close on Nov 17, 2026Market cap $60.32MP/E –Yield –
LENSAR, Inc. grew revenue 3.3% to $60.26M over the twelve months to Jun 30, 2026. Free cash flow was -$14.91M. At the latest close the market valued the company at $60.32M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $60.32M
- P/E ratio
- –
- Price to sales
- 1.00
- Price to book
- 4.05
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $60.26M
- Net income
- $34.70M
- EPS, diluted
- -$0.33
- Free cash flow
- -$14.91M
- Book value per share
- $0.65
- Diluted shares
- 23M
Trading
- Next earnings
- Mar 30, 2027 (estimated, before the open)
- Previous close
- $5.29
- Open
- $5.27
- Day's range
- $4.89 – $5.40
- Volume
- 111,964
- Average volume (20 days)
- 74,543
- Index membership
- Russell 2000 (since Jun 2025)
- 52-week range
- $4.30 – $12.94
- RSI (14 days)
- 36.1
- Volatility (1 year)
- 69.5%
- Relative volume
- 1.22×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | LNSR | S&P 500 | Difference | LNSR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.3% | -4.0% | −11.3 pts | ||
| 3 months | -39.3% | -5.0% | −34.3 pts | ||
| Year to date | -57.8% | +8.2% | −66.0 pts | ||
| 1 year | -50.2% | +11.2% | −61.4 pts | ||
| 3 years | +124.2% | +68.5% | +55.7 pts | +30.9% | +19.0% |
| 5 years | -32.8% | +67.3% | −100.1 pts | -7.7% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lensar filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Lensar
Surgical & Medical Instruments & Apparatus
LENSAR, Inc. is a commercial-stage medical device company that develops, designs, and markets advanced femtosecond laser systems. Its primary offerings include the LENSAR Laser System and the next-generation ALLY Robotic Cataract Laser System, which integrate proprietary technologies such as advanced imaging and procedural planning to support ophthalmic procedures. The company’s systems are designed for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its customer base consists of ophthalmic cataract surgeons, practices, and ambulatory surgery centers.
Company profile, executives and historyLensar stock: common questions
What is Lensar's stock price?
LNSR closed at $4.91 on Nov 17, 2026, down 7.18% on the day. Over the past 52 weeks it traded between $4.30 and $12.94.
What is Lensar's market cap?
Lensar was worth $60.32M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is LNSR's P/E ratio?
Lensar lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.33), so it has no meaningful P/E ratio.
How much revenue does Lensar make?
Lensar reported revenue of $60.26M for the twelve months to Jun 30, 2026, up 3.3% from a year earlier.
Does Lensar pay a dividend?
No. Lensar has not paid a cash dividend over the last twelve months.
When does Lensar report earnings next?
Lensar is expected to report Q4 FY2026 results on Mar 30, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LNSR stock performed over the past year?
Including dividends, LNSR returned -50.2% over the past year, against +11.2% for the S&P 500.
Who are Lensar's competitors?
Companies most similar to Lensar by business, industry and size include SGHT, SSII, CVRX, APYX, TELA.
See a number that looks wrong?